靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2016-04-30 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2021-11-02 |
Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)
The purpose of this study is to determine whether CBT124 and Avastin® are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin® (pharmacokinetics is nested in this study for Indian patients).
100 项与 Cipla BioTec Ltd. 相关的临床结果
0 项与 Cipla BioTec Ltd. 相关的专利(医药)
100 项与 Cipla BioTec Ltd. 相关的药物交易
100 项与 Cipla BioTec Ltd. 相关的转化医学